Brain meningioma is a usually slow-growing tumor that starts in the coverings of the brain. Many people with brain meningioma have headaches, seizures, or changes in vision or personality. It is more common in adults, especially women, and often found during imaging for new symptoms or a routine check. Most tumors are benign and grow slowly, so many people live for years and do well. Treatment can include watchful waiting, surgery, or focused radiation, and follow-up scans track changes over time.
Overview
Brain meningiomaSymptoms
Brain meningioma symptoms depend on tumor size and location. Early symptoms of brain meningioma may include headaches, vision changes, or seizures; some cause weakness, numbness, balance or speech problems, memory or personality changes. Many remain silent and are found incidentally.
Outlook and prognosis
Many people with brain meningioma do well, especially when tumors are small, slow-growing, and found early. Surgery and focused radiation often control growth for years, with regular MRI follow-up. Outlook varies by tumor location, grade, and overall health.
Causes and risk factors
Brain meningioma risk rises with older age, female sex hormones, and obesity. Prior head radiation is the strongest environmental risk. Some cases relate to inherited changes, especially NF2; most are sporadic without clear cause.
Genetic influences
Genetics plays a meaningful role in brain meningioma risk and behavior. Most tumors carry somatic mutations (for example, NF2), while inherited syndromes like neurofibromatosis type 2 raise lifetime risk. Tumor genetics can guide prognosis and, in some cases, targeted therapy options.
Diagnosis
Doctors diagnose brain meningioma using your history, a neurologic exam, and imaging. MRI with contrast is standard; CT helps when MRI isn’t possible. A biopsy or surgical removal confirms the diagnosis of brain meningioma and grades the tumor.
Treatment and drugs
Brain meningioma treatment is tailored to tumor size, location, growth, and symptoms. Options often include careful MRI monitoring, precise surgery to remove the tumor, and targeted radiation such as stereotactic radiosurgery. Medicines can help manage headaches, seizures, swelling, and recovery.
Symptoms
Brain meningioma symptoms often build slowly because these tumors tend to grow over months or years. Early symptoms of brain meningioma can be easy to miss and may look like everyday issues, such as lingering headaches, tiredness, or small changes in focus or mood. Symptoms vary from person to person and can change over time. What you notice depends on where the tumor presses, so vision, speech, balance, or sensation may be affected first.
New or worsening headaches that don’t settle with usual pain relievers are common. They may be worse in the morning or with coughing or bending. These can happen with brain meningioma as pressure builds or nearby tissues get irritated.
Spells of shaking, staring, or sudden confusion can occur, even if you’ve never had one before. You might feel very tired or have a sore tongue afterward. A first seizure in an adult is a common way a brain meningioma is first noticed.
Blurry or double vision, trouble reading, or loss of side vision can develop. Some bump into door frames or misjudge steps on a staircase. This can happen when a brain meningioma affects the nerves or areas that process sight.
Hearing loss in one ear or constant ringing can creep in. Following conversations, especially in noisy places, may become harder. Nearby growths can press on hearing and balance pathways.
How people usually first notice Brain meningioma?
Many people first notice a brain meningioma when slow, subtle changes add up—more frequent headaches, new spells of nausea, or a sense that concentration or memory isn’t quite the same as before. Depending on where the tumor sits, early signs can include vision blurriness or double vision, one‑sided weakness or numbness, hearing changes or ringing in one ear, new seizures, or gradual shifts in personality or mood; these symptoms often build over months because most meningiomas grow slowly. Often, a scan done for persistent headaches, a concussion, or another unrelated issue is how a meningioma is first discovered.
Types of Brain meningioma
Brain meningioma can look and feel different depending on the tumor’s grade and where it sits in the brain. Day to day, that can mean headaches for one person, while another mostly notices vision changes or weakness on one side. Clinicians often describe them in these categories: grade (how the cells look under a microscope), location, and growth pattern, and these influence symptoms and treatment options. If you’re comparing types of brain meningioma, differences usually show up in speed of growth and which brain functions are affected.
Grade 1 (benign)
These are the most common and usually slow-growing. Symptoms tend to build gradually, such as headaches, seizures, or changes in vision or hearing. Many people do well with surgery alone.
Grade 2 (atypical)
These grow faster and are more likely to come back after treatment. Symptoms may progress over months instead of years and can include worsening headaches, weakness, or coordination problems. Radiation is often considered after surgery.
Grade 3 (anaplastic)
These are rare but aggressive and can invade nearby brain tissue. Symptoms can escalate quickly with significant neurological changes like seizures, speech difficulty, or personality changes. Treatment typically combines surgery, radiation, and sometimes medicines.
Skull base location
Tumors near the base of the skull often affect vision, hearing, or facial movement first. People may notice double vision, ringing in the ears, or numbness in the face. Surgery can be more complex due to nearby nerves and blood vessels.
Convexity location
These form on the outer surface of the brain and may cause headaches, seizures, or weakness on one side. Symptoms often reflect pressure on the part of the brain just under the tumor. Many are accessible for surgical removal.
Parasagittal/falcine
These grow along the midline and can affect leg strength, balance, or bladder control. People may develop gradual weakness or trouble walking. Swelling around the tumor can heighten symptoms.
Sphenoid wing
These sit near structures for vision and eye movement. Blurry vision, double vision, or bulging of one eye can be early clues. Headaches around the temple are also common.
Olfactory groove
These can start with loss of smell and subtle changes in taste or mood. As they enlarge, headaches and vision changes can develop. Loved ones may recognize certain types sooner than the person experiencing them.
Spinal meningioma
When meningioma occurs along the spine, symptoms differ from brain locations. People often notice back pain, numbness, or leg weakness that worsens over time. Bowel or bladder changes can appear in more advanced cases.
What genetics can tell you about symptoms
Certain inherited changes, like NF2 gene variants, can trigger multiple meningiomas that grow earlier, causing headaches, seizures, or vision and hearing changes. Other syndromes (SMARCB1, SMARCE1) are tied to spinal or clear cell meningiomas, influencing pain, weakness, or balance problems.
Causes and risk factors
Brain meningioma develops when cells in the membranes around the brain start to grow too much. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t). Key risk factors for brain meningioma include prior head or neck radiation, older age, and being female. Rare inherited changes, such as NF2 gene changes, and a family history can also increase risk. Obesity and some hormone exposures may contribute, but everyday items like cell phones have not shown clear links.
Environmental and biological risk factors
When a brain meningioma is found, many people want to know what might have set the stage. Doctors often group risks into internal (biological) and external (environmental). These are about chances of developing a tumor, not the early symptoms of brain meningioma. Here are key biological and environmental influences linked with risk.
Risk rises with age, especially after midlife. As cells age, natural repair processes can lag, making abnormal growths more likely. Children can be affected, but it’s uncommon.
Meningiomas are diagnosed more often in women than in men. Many tumors carry progesterone and sometimes estrogen receptors, which may influence risk. This difference appears after puberty and continues into later life.
Exposure to ionizing radiation to the head or neck increases long-term risk of brain meningioma. This includes past medical treatments such as older scalp therapies or radiotherapy for other cancers. Higher cumulative doses generally translate to higher risk.
Long-term occupational exposure to ionizing radiation can raise risk. This has been observed historically in certain medical or nuclear settings, especially before strict protections were adopted. Modern shielding and monitoring have reduced typical exposures.
Genetic risk factors
Genetics play a central role in how some brain meningiomas start, either through inherited changes that raise risk or DNA changes that develop only in the tumor. Understanding genetic risk factors for brain meningioma can guide decisions about genetic counseling and monitoring. Carrying a genetic change doesn’t guarantee the condition will appear. Below are key inherited risks and tumor gene changes linked to this condition.
NF2 syndrome: An inherited change in the NF2 gene greatly increases the chance of multiple meningiomas, often starting earlier in life. Families may notice other nerve-related tumors as well, such as those affecting hearing.
NF2 gene loss: In many sporadic meningiomas, tumor cells lose part of chromosome 22 that holds the NF2 gene, which helps trigger growth. These changes happen after birth within the tumor and are not usually passed down.
SMARCE1 changes: Rare inherited changes can predispose to clear cell meningioma, sometimes appearing in childhood or young adulthood. Several relatives in the same family may be affected.
SMARCB1 changes: Inherited changes in this gene can occur in families with multiple meningiomas and schwannomas. Risk can vary within families, and some relatives may never develop tumors.
BAP1 syndrome: An inherited BAP1 change can increase risk for a rare, aggressive form called rhabdoid meningioma and is part of a broader cancer predisposition. Genetic testing may be suggested when this pattern appears at a young age or in a family.
Tumor driver genes: Some meningiomas carry changes in AKT1, TRAF7, KLF4, SMO, or PIK3CA that shape where the tumor arises and how it behaves. These changes are almost always limited to the tumor itself and do not run in families.
Family history: Having a first-degree relative with meningioma raises personal risk modestly compared with the general population. Most people with brain meningioma have no known inherited cause.
Aggressiveness markers: Some tumors acquire changes such as TERT promoter mutations or loss of CDKN2A/B that signal faster growth or higher chance of return. These are tumor features that guide treatment planning rather than inherited risks.
Lifestyle risk factors
Several modifiable habits appear to influence the chances of developing, or the course of, brain meningioma, largely through hormone and metabolic pathways. Evidence is still evolving, but weight management, physical activity, and decisions about hormonal medications are the most consistent lifestyle risk factors for brain meningioma. Diet matters mostly through its impact on body weight, insulin resistance, and inflammation. Discuss any medication or major lifestyle change with your clinician, especially if you already have a meningioma.
Higher BMI is associated with a greater risk of meningioma in several studies. Body fat can raise estrogen/progestin levels and inflammation, which may support tumor development.
Sedentary time promotes weight gain and insulin resistance, both linked to higher meningioma risk. Regular activity can help regulate sex hormones and inflammation, potentially lowering risk.
Prolonged or high-dose progestins (such as cyproterone acetate and some similar agents) have been associated with meningioma development and growth. Reviewing contraceptive or acne treatments may be warranted, and stopping certain progestins can lead to stabilization in some cases.
Some studies link estrogen-progestin or progestin-only HRT to a higher meningioma risk. If HRT is needed, use the lowest effective dose and reassess regularly, and avoid progestin-heavy regimens if you have a meningioma.
Risk prevention
You can’t fully prevent brain meningioma, but you can lower risk by limiting certain exposures and staying on top of personal risk factors. Some prevention is universal, others are tailored to people with specific risks. If you’re higher risk—because of prior head radiation or a family history—specialized monitoring may help. Knowing early symptoms of brain meningioma won’t prevent it, but it can lead to quicker evaluation if something changes.
Ask if scans are truly necessary and whether MRI or ultrasound could answer the question without radiation. When X‑rays or CT are needed, request shielding and the lowest effective dose.
If you work around radiation, follow safety rules every time. Use shielding, wear a dosimeter, and keep exposure as low as reasonably achievable.
Talk with your clinician about menopausal hormone therapy or high‑dose progestins and whether non‑hormonal options fit your goals. If hormones are needed, use the lowest effective dose for the shortest time that works.
Higher body weight is linked with a greater chance of meningioma. Balanced eating and regular physical activity can help reduce this risk over time.
Transmission
Brain meningioma doesn’t spread between people—it isn’t contagious through touch, the air, sex, blood, or close contact of any kind. Most brain meningiomas are not inherited; they usually happen when cells in the brain’s coverings acquire genetic changes over time, so there is no genetic transmission of brain meningioma in most families. Rarely, an inherited syndrome (such as neurofibromatosis type 2) can raise the chance of developing one or more meningiomas; this is how brain meningioma is inherited in a small subset of people. Even then, having a parent with a meningioma does not mean you will definitely develop one, and most people with brain meningioma have no family history.
When to test your genes
Brain meningioma is usually not inherited, so most people don’t need genetic testing. Consider testing if you were diagnosed at a young age, have multiple or recurrent meningiomas, have family history of similar tumors, or features of syndromes like NF2; testing can guide surveillance and tailor treatment decisions.
Diagnosis
Brain meningioma is usually found when symptoms or an incidental scan raises concern. Doctors usually begin with a careful history and neurological exam before ordering imaging. If you’re wondering how brain meningioma is diagnosed, MRI with contrast is the main test, and tissue analysis confirms the answer when needed. Some cases are spotted during routine imaging done for headaches or after a minor injury.
Your provider asks about headaches, seizures, vision or hearing changes, and how long symptoms have been present. They’ll also ask about past radiation exposure and family history.
The exam checks strength, balance, reflexes, vision, and speech. Findings help point to the tumor’s location and urgency of testing.
This is the primary imaging test to evaluate a suspected meningioma. It shows the tumor’s size, exact location, and relationship to nearby brain structures and veins.
A CT scan can detect bone changes and calcium within the tumor, which are common in meningioma. It’s also used if someone cannot have an MRI.
Stages of Brain meningioma
Brain meningioma does not have defined progression stages. Instead, doctors describe its behavior by a pathology grade (how the cells look under the microscope) and by whether it grows or stays stable on brain scans, because these tumors don’t follow a single step-by-step course. Diagnosis relies on MRI or CT to locate and size the tumor, and a biopsy or surgical removal can confirm the pathology grade; follow-up imaging at set intervals checks for change, especially if early symptoms of brain meningioma are mild or the tumor was found incidentally. Many people feel reassured knowing what their tests can—and can’t—show.
Outlook and prognosis
Many people ask, “What does this mean for my future?”, and the short answer is that most brain meningiomas grow slowly and are treatable. Small tumors found by chance may simply be watched with regular scans, and many people never need an operation. Symptoms often relate to location—maybe new headaches, vision changes, or seizures—and early care can make a real difference in keeping daily life steady.
Doctors call this the prognosis—a medical word for likely outcomes. Survival is generally favorable: 5-year survival for benign brain meningioma is high, and many people live decades after diagnosis. Risk rises when the tumor is atypical or malignant, or if it presses on critical brain areas. Age, overall health, and how completely a surgeon can remove the tumor all shape the outlook. Radiation can control growth when surgery isn’t possible or when a small remnant remains after surgery.
Knowing what to expect can ease some of the worry. For many, the long-term plan includes periodic MRIs, seizure control if needed, and focused radiation if scans show growth. Recurrence can happen years later, especially with atypical or malignant types, so long-term follow-up matters. The future may look uncertain now, but with ongoing care, many people maintain work, family life, and independence. Talk with your doctor about what your personal outlook might look like, and ask about early symptoms of brain meningioma that should prompt a call between visits.
Long-term effects
Brain meningioma can leave lasting effects that depend on the tumor’s size, location, and the type of treatment you receive. Some people return to familiar routines with few changes, while others notice ongoing issues with thinking, senses, or movement. Long-term effects vary widely, and they don’t always match how severe the tumor once looked on scans. This outlook can also change slowly over years rather than weeks or months.
Brain irritation from the tumor or scar tissue can lead to seizures even after treatment. Some people need long-term seizure control, while others outgrow them over time.
Attention, memory, or processing speed can feel slower, especially after larger tumors or radiation. Early symptoms of brain meningioma may settle, but subtle thinking changes can linger. These shifts often become clearer during complex tasks or multitasking.
Pressure changes and scar tissue can leave a background headache that flares with stress or fatigue. For many, headaches improve over months, but a minority have long-term pain.
Tumors near the optic nerves or ear pathways can cause lasting blurriness, blind spots, or hearing loss. Even after successful treatment, damaged nerves may not fully recover.
How is it to live with Brain meningioma?
Living with a brain meningioma often means adjusting to symptoms that can ebb and flow—headaches, fatigue, trouble concentrating, or brief lapses in memory—while working around follow-up scans and, for some, recovery from surgery or radiation. Many people return to most daily activities, but they may pace tasks, plan rest, and use reminders to keep focus steady, especially on days when symptoms flare. Partners, family, and coworkers can be affected too, learning to recognize subtle changes in mood or thinking and offering practical help with appointments, transportation, or household routines. With good communication and a tailored care plan, most find a new rhythm that protects health while preserving independence and connection.
Treatment and drugs
Treatment for brain meningioma depends on tumor size, location, growth rate, symptoms, and your overall health. Small, slow-growing meningiomas that aren’t causing problems are often monitored with periodic MRI scans, while symptomatic or enlarging tumors are usually treated with surgery to remove as much as safely possible. If some of the brain meningioma remains, or if surgery isn’t a good option due to location or health factors, focused radiation (such as stereotactic radiosurgery) can help control growth. Medicines don’t shrink the tumor, but doctors may use drugs to ease symptoms like seizures, swelling, or headaches; a doctor may adjust your dose to balance benefits and side effects. Supportive care can make a real difference in how you feel day to day, and follow-up imaging is important to watch for any changes over time.
Non-drug treatment
Living with brain meningioma can affect balance, speech, vision, energy, and how you manage daily tasks at home or work. Early symptoms of brain meningioma—like new headaches, double vision, or subtle memory slips—can guide which supportive therapies matter most. Non-drug treatments often lay the foundation for recovery and quality of life, whether you’re being monitored, planning radiation, or recovering after surgery. Your care team will tailor these options to your symptoms, tumor location, and personal goals.
Regular MRI scans and check-ins track the tumor and your symptoms. This approach suits small, slow-growing meningiomas without bothersome signs.
Targeted beams (stereotactic radiosurgery or fractionated radiation) shrink or control a tumor without an incision. Planning often includes a custom head frame or mask to protect healthy brain tissue.
Strength, balance, and coordination training can reduce falls and improve walking. Therapists also teach home exercises and safe movement strategies.
Training focuses on everyday tasks like dressing, cooking, and using adaptive tools. Therapists can suggest home modifications and energy-conserving routines.
Your genes may have an impact on how drugs work for you
Two people can take the same brain meningioma drug yet respond differently because genes affect how the body activates, breaks down, or transports medicines. Pharmacogenetic testing can sometimes guide dosing or drug choice, helping balance effectiveness with fewer side effects.
Pharmacological treatments
Medicines for brain meningioma mainly manage symptoms like swelling and seizures, and are sometimes used when surgery or radiation aren’t options. A few targeted drugs may slow tumor growth in recurrent or higher-grade cases, often off-label or in clinical trials. Not everyone responds to the same medication in the same way. Your care team will match drugs to your situation and adjust over time.
Dexamethasone can quickly shrink swelling around the tumor to ease headaches, nausea, or weakness. This often relieves pressure-related headaches, one of the early symptoms of brain meningioma. Doctors usually taper it to the lowest effective dose to limit side effects like high blood sugar or sleep changes.
Levetiracetam or lamotrigine are common choices if seizures occur with brain meningioma. They aren’t routinely started if you’ve never had a seizure. Let your team know about other medicines to avoid interactions.
Acetaminophen (paracetamol) is often used first; some may use NSAIDs if safe for their stomach and kidneys. Avoid frequent use, which can cause rebound headaches. Check with your team if you’re on steroids, blood thinners, or have bleeding risks.
Bevacizumab, an anti-VEGF drug, can reduce brain swelling and may slow growth in recurrent brain meningioma. It can lower steroid needs for some people. Side effects can include high blood pressure, bleeding risks, and delayed wound healing.
Genetic influences
Most brain meningiomas happen by chance, caused by gene changes that arise only in the tumor cells over time. DNA testing can sometimes identify these changes and may help doctors predict how the tumor could behave or respond to treatment. A smaller group of people have an inherited tendency, most often due to a condition called neurofibromatosis type 2 (NF2), which can lead to multiple meningiomas at a younger age. Other rare inherited syndromes can also raise risk, but these are uncommon. Even when someone carries a risk gene, many never go on to develop a brain meningioma. If several relatives have brain meningioma or if tumors appear early, genetic counseling and, in some cases, genetic testing for brain meningioma can help clarify your family’s risk.
Is Brain meningioma genetic?
Genetics plays a meaningful role in brain meningioma risk and behavior. Most tumors carry somatic mutations (for example, NF2), while inherited syndromes like neurofibromatosis type 2 raise lifetime risk. Tumor genetics can guide prognosis and, in some cases, targeted therapy options.
Pharmacogenetics—how genetics influence drug effects
Treatment choices for brain meningioma increasingly take the tumor’s genetics into account, especially when surgery or radiation alone isn’t enough. Changes in genes such as NF2, or in growth‑signal genes like SMO or AKT1, can point toward targeted medicines or clinical trials designed to block the specific pathways those tumors use; in specialized centers, genetic testing for brain meningioma may help identify these options. Some meningiomas show somatostatin receptors, which can guide imaging and, in select cases, medicines that attach to those receptors based on the tumor’s biology. Doctors can use your genetic information to help match therapies and dosing, and to decide whether pharmacogenetic testing for supportive drugs (like anti‑seizure or pain medicines) might reduce side effects. For people with brain meningioma who need anti‑seizure treatment, inherited differences in drug‑processing enzymes can influence which medicine and dose are safest and most effective. Genes are only part of the picture, so results are interpreted alongside the tumor’s grade, MRI findings, prior treatments, and your overall health.
Interactions with other conditions
People with brain meningioma may also have other conditions that affect how the tumor behaves and how it’s treated. Doctors call it a “comorbidity” when two conditions occur together. A well-known example is neurofibromatosis type 2, a genetic syndrome linked to multiple meningiomas and tumors on the hearing nerves; symptoms from each can overlap, like hearing changes or balance problems. Prior cancer treated with head radiation, and some long-term progesterone-like hormone therapies, have been associated with meningiomas, so your care team will often review past treatments and medicines. In people with seizure disorders, what seems like early symptoms of brain meningioma may blend into their usual pattern, and blood thinners for heart or stroke prevention can complicate surgical planning and bleeding risk. These connections aren’t the same for everyone, so coordinated care across specialties helps tailor safe, effective treatment for your situation.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described sudden headaches, changes in sight, or weakness that seemed to grow slowly over months. Families and communities once noticed patterns in which an otherwise healthy adult developed seizures or personality shifts and, years later, was found to have a growth inside the skull. These lived experiences shaped early thinking about what we now call brain meningioma, a tumor that arises from the membranes covering the brain.
First described in the medical literature as firm, well-defined growths on the brain’s lining during 19th‑century autopsies, brain meningioma was initially understood only through symptoms, later confirmed after death. Surgeons in the early 1900s began attempting removal; as anesthesia, sterile technique, and better instruments advanced, operations shifted from rare and risky to planned procedures with real chances of recovery. Early reports called it “dural endothelioma,” though the term has largely been replaced as pathology improved and scientists learned these tumors come from cells in the meninges.
From early theories to modern research, the story of brain meningioma reflects steady progress in seeing what was once hidden. The rise of brain imaging changed everything. With pneumoencephalography and angiography mid‑century, doctors could infer a mass by how normal structures shifted. The arrival of CT in the 1970s and MRI in the 1980s allowed direct visualization. Over time, descriptions became more precise: typical meningiomas are slow‑growing, often benign on pathology, and sometimes found incidentally when scans are done for other reasons.
Advances in genetics added another layer. Inheritance patterns were noticed in people with neurofibromatosis type 2, who can develop multiple meningiomas, and later studies identified changes in genes such as NF2 and others within the tumor cells themselves. This helped explain why some tumors behave quietly for years while a minority grow faster or return after surgery. It also guided grading systems and follow‑up plans, linking what doctors saw under the microscope with how tumors acted over time.
Radiation history played a role as well. Mid‑20th‑century therapeutic radiation and even low‑dose scalp radiation used in childhood for benign conditions were later tied to a higher risk of meningioma decades on. Recognizing this shifted public health practices and informed long-term monitoring for exposed groups.
With each decade, treatment options broadened. Microsurgery reduced complications; imaging‑guided planning improved safety; and focused radiation, such as stereotactic radiosurgery, offered a non‑invasive option for selected tumors, especially those in hard‑to‑reach areas. Follow‑up moved from symptom‑based to scan‑based, allowing many living with brain meningioma to be monitored and treated only if growth appears.
Knowing the condition’s history helps explain today’s approach: careful imaging, attention to tumor features and genetics, and tailored care that may range from watchful waiting to surgery or targeted radiation. Despite evolving definitions, the arc has consistently bent toward safer diagnosis, more personalized decisions, and better quality of life for people with brain meningioma.